Device Trial Radar · NCT04776031
Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes
Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Feb 15, 2021
Primary completion
Mar 14, 2023
Study completion Mar 14, 2023
Sponsor
- Lead sponsor
- Lutronic Vision, IncNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Neuroscience Trials Australia
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of the R:GEN Laser System in subjects with the early stages of age-related macular degeneration.
Conditions
- Early Age Related Macular Degeneration (Disorder)
Interventions
R:GEN Laser SystemDevice
Laser Treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- To access the safety and tolerability of the R:GEN Laser System in subjects with the early stages of AMD.Time frame: up to 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Eye Research Australia - Royal Victorian Eye & Ear Hospital
East Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.